Disrupting aberrant EGFR catalytic trimers reverses T790M gefitinib resistance
Selene K. Roberts, Ioannis Galdadas, Nicola Piasentin, Sarah R. Needham, Benjamin Michael Davis, Laura C. Zanetti-Domingues, Rico C.H. Man, David T. Clarke, Andrew H. A. Clayton, Daniel J. Rolfe, Gilbert O. Fruhwirth, Francesco Luigi Gervasio, Marisa L. Martin-Fernandez
This study shows that disrupting pathological EGFR catalytic trimers reverses gefitinib resistance by rewiring signaling and slowing tumor growth.
bioRxiv · Sep 30, 2026 · PreprintCancer Biology